|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 18.02 billion
|
|
Market Size (2030)
|
USD 25.94 billion
|
|
CAGR (2025-2030)
|
6.22%
|
|
Fastest Growing Segment
|
Hospitals
|
|
Largest Market
|
North America
|
Market Overview
Global Oral Anti-Diabetic Drugs Market
was valued at USD 18.02 Billion in 2024 and is expected to reach USD 25.94
Billion in the forecast period with a CAGR of 6.22% through 2030. The
global Oral Anti-Diabetic Drugs market has witnessed significant growth and
transformation in recent years, driven by the escalating prevalence of diabetes
and ongoing advancements in pharmaceutical research and development. As the
demand for effective diabetes management continues to rise, this market plays a
pivotal role in providing treatment options that cater to the diverse needs of
diabetic patients. One of the primary factors fueling the growth of the Oral
Anti-Diabetic Drugs market is the escalating prevalence of diabetes worldwide.
Diabetes, a chronic metabolic disorder characterized by elevated blood glucose
levels, affects millions of people globally. Factors such as sedentary
lifestyles, unhealthy dietary habits, and an aging population contribute to the
increasing incidence of diabetes. This rising patient pool necessitates a wide
range of treatment options, making the Oral Anti-Diabetic Drugs market more
relevant than ever. The Oral Anti-Diabetic Drugs market boasts a diverse
portfolio of drug classes, each designed to address different aspects of
diabetes management. These drug classes include Sulfonylureas, Biguanides, Glucagon-Like
Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter 2 (SGLT2)
Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, etc. The Oral
Anti-Diabetic Drugs market is characterized by robust competition, with both
established pharmaceutical companies and emerging players vying for market
share boosting the market demand for Global Oral Anti-Diabetic Drugs Market.
Key
Market Drivers
Increasing Global Diabetes
Prevalence
One The escalating global prevalence of diabetes stands as a primary and influential driver for the Oral Anti-Diabetic Drugs (OAD) market. Recent data from the International Diabetes Federation (IDF) indicates that in 2024, approximately 589 million adults aged 20 to 79 are living with diabetes, accounting for about 11.1% of the global adult population. Projections suggest this number will rise to 643 million by 2030 and reach 853 million by 2050. Similarly, a 2024 study published in The Lancet estimates that in 2022, around 828 million adults aged 18 and older had diabetes, highlighting a significant increase from previous years.
This alarming rise is fueled by factors such as sedentary lifestyles, poor dietary choices, and an aging population. Modern lifestyles characterized by desk-bound jobs, prolonged screen time, and reduced physical activity have contributed to an increased risk of obesity and, subsequently, type 2 diabetes. As the number of individuals living with diabetes continues to surge, so does the demand for effective treatment options, making the Oral Anti-Diabetic Drugs market indispensable.
Oral anti-diabetic drugs are positioned at the forefront of this battle against diabetes. These medications offer a versatile approach to managing the disease, catering to the diverse needs of diabetic patients. Pharmaceutical companies, recognizing the urgency of the diabetes epidemic, have accelerated their research and development efforts in response. Advancements in drug formulations have been a pivotal driving force behind the market's growth. Traditionally, injectable glucagon-like peptide-1 (GLP-1) receptor agonists have been pivotal in diabetes management. However, the introduction of oral GLP-1 receptor agonists has marked a significant breakthrough. These oral tablets mimic the effects of GLP-1, promoting insulin secretion and weight loss, and have expanded accessibility and acceptance among patients.
The escalating prevalence of diabetes serves as a wake-up call, demanding innovative solutions to curb its impact and provide effective treatment options to those affected. With the continuous rise in diabetes cases, the importance of oral anti-diabetic therapies is becoming increasingly pronounced, ensuring that these medications remain at the forefront of chronic disease management worldwide..
Advancements in Drug
Formulations
Advancements in drug formulations are significantly propelling the growth of the Oral Anti-Diabetic Drugs (OAD) market. Pharmaceutical companies are investing heavily in research and development to create safer, more effective, and more convenient medications for diabetic patients.
One notable innovation is the development of fixed-dose combination (FDC) therapies, which combine multiple medications into a single tablet. This approach simplifies treatment regimens and enhances patient compliance. A study involving over 23,000 patients found that those on FDC therapy had a 28% higher likelihood of adherence compared to those on separate-pill regimens . Additionally, in a study conducted in India, 58% of patients preferred FDCs when multiple oral anti-diabetic drugs were prescribed .
Extended-release formulations of existing OADs have also contributed to market growth. For instance, metformin, a widely prescribed biguanide, now has extended-release versions that allow for once-daily dosing. These formulations provide sustained blood sugar control and greater convenience for patients. Studies have shown that patients on metformin extended-release (XR) demonstrate higher adherence rates—up to 97.2%—compared to those on immediate-release (IR) formulations . Moreover, metformin XR is associated with significantly fewer gastrointestinal side effects, such as diarrhea and bloating, enhancing patient tolerability .
Furthermore, advancements in genetics and biomarker research have paved the way for more personalized medicine approaches in diabetes care. By identifying specific genetic markers or biomarkers that influence a patient's response to medication, healthcare providers can tailor treatment plans to individual needs, optimizing the effectiveness of oral anti-diabetic drugs and minimizing side effects.
These innovations in drug formulations not only improve patient outcomes but also underscore the dynamic nature of the OAD market, reflecting a commitment to addressing the evolving needs of individuals with diabetes..
Increasing Awareness and
Diagnosis
Growing awareness about diabetes
and its management is a vital driver for the Oral Anti-Diabetic Drugs market.
Healthcare campaigns, patient education initiatives, and the efforts of medical
professionals have contributed to higher rates of diabetes diagnosis. Early
diagnosis leads to timely interventions and a greater likelihood of oral
anti-diabetic drug use. Moreover, patients who are aware of the potential
complications associated with uncontrolled diabetes are more likely to adhere
to their prescribed medication regimens.
The benefits of early diagnosis
are manifold. Firstly, it empowers individuals with the knowledge of their
condition, enabling them to take proactive measures to manage their diabetes.
Secondly, it allows healthcare providers to initiate treatment early,
minimizing the risk of complications and optimizing glycemic control. Thirdly,
it opens the door to timely and informed discussions about treatment options,
including the use of oral anti-diabetic drugs. With increased awareness and
diagnosis, the demand for oral anti-diabetic drugs has surged. These
medications have become integral components of diabetes management plans,
particularly for individuals with type 2 diabetes. The diverse classes of oral
anti-diabetic drugs, such as sulfonylureas, biguanides, dipeptidyl peptidase-4
(DPP-4) inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors,
offer a range of treatment options tailored to individual patient needs. Moreover,
early diagnosis has had a profound impact on patient adherence to prescribed
medication regimens. Patients who are aware of their condition and its
potential consequences are more likely to take their medications as directed.
This adherence is crucial for achieving and maintaining optimal glycemic
control, which is essential in preventing diabetes-related complications.
Expanding Geriatric Population
The expanding geriatric population is emerging as a critical driver of the Oral Anti-Diabetic Drugs (OAD) market, as older adults are particularly vulnerable to type 2 diabetes due to physiological changes that occur with aging. According to the International Diabetes Federation (IDF), in 2023, an estimated 266 million people aged 65 and older were living with diabetes globally. This number is projected to rise to 276 million in 2024 and further to 285 million by 2025, underscoring the growing burden of diabetes within the elderly population.
This demographic shift is fueled by increasing life expectancy and improved access to healthcare services, resulting in a steady rise in the elderly population worldwide. The United Nations reports that the global population aged 65 years and older reached 771 million in 2023, and this figure is expected to climb to 798 million by 2024 and approximately 825 million by 2025. As this population expands, so does the demand for oral anti-diabetic therapies that are convenient, safe, and effective for managing chronic conditions like diabetes in aging individuals.
Oral anti-diabetic drugs provide an essential solution for glycemic control among the elderly, especially those who may face difficulties with injectable medications. Formulations tailored for older patients—such as extended-release tablets or fixed-dose combinations—enhance adherence and reduce treatment complexity. This convergence of aging demographics and rising diabetes prevalence makes the geriatric segment a key target for pharmaceutical innovation and market expansion in the OAD landscape.
Download Free Sample Report
Key Market Challenges
High Healthcare Costs
Diabetes management is associated with substantial healthcare costs, including medications, monitoring devices, and frequent medical consultations. These costs can place a significant financial burden on healthcare systems, insurers, and patients. Affordability and accessibility to oral anti-diabetic drugs are critical issues, particularly in low- and middle-income countries, where many individuals may struggle to access and afford necessary medications. One of the most prominent hurdles in the path of effective diabetes management is the financial burden it places on individuals and healthcare providers. Diabetes care encompasses a range of costs, including the price of oral anti-diabetic drugs, monitoring devices, regular medical check-ups, and potential hospitalization for diabetes-related complications. These expenses can accumulate rapidly and strain the financial resources of patients and their families.
The cost of oral anti-diabetic drugs, which are fundamental to controlling blood sugar levels, is a substantial component of diabetes-related healthcare expenses. While these medications are indispensable for many patients, their prices can be prohibitive, especially for those without adequate insurance coverage.
Side Effects and Safety
Concerns
Many oral anti-diabetic drugs
come with potential side effects, and not all patients tolerate these
medications well. For instance, some sulfonylureas can cause hypoglycemia, and
certain medications may be associated with weight gain. Balancing the benefits
of these drugs with potential adverse effects can be challenging for both
patients and healthcare providers.
One of the primary concerns
associated with oral anti-diabetic drugs is the risk of hypoglycemia, a
condition characterized by dangerously low blood sugar levels. Certain classes
of these drugs, such as sulfonylureas, stimulate the pancreas to release more
insulin. While this helps lower blood sugar levels, it can sometimes lead to
excessive insulin production and subsequent hypoglycemia. Severe hypoglycemia
can be life-threatening, and the fear of this side effect can deter patients
from adhering to their medication regimens. Another concern is the potential
for weight gain associated with some oral anti-diabetic drugs, particularly
sulfonylureas and thiazolidinediones. Weight gain can exacerbate other health
issues, such as obesity and cardiovascular disease, which are common
comorbidities in individuals with diabetes. The fear of weight gain may lead
patients to avoid or discontinue medications, compromising their glycemic
control.
Medication Adherence
Medication adherence remains a
pervasive challenge in diabetes management. Patients are often prescribed
complex medication regimens that involve multiple oral anti-diabetic drugs, and
maintaining strict adherence to these regimens can be difficult. Non-adherence
can lead to poor glycemic control, increased risk of complications, and higher
healthcare costs. One of the primary reasons for non-adherence is the
complexity of medication regimens. Many individuals with diabetes are
prescribed multiple medications, each with its own dosing schedule. Managing
this complexity can be overwhelming, leading to confusion and missed doses.
Moreover, the fear of potential side effects, such as hypoglycemia or weight
gain, can discourage patients from taking their medications as prescribed.
Patients may also discontinue
their medications due to perceived ineffectiveness or a lack of immediate
symptomatic relief. Unlike some medical conditions where symptom improvement is
noticeable shortly after starting treatment, diabetes management often requires
consistent, long-term medication use to prevent complications, making it
challenging for patients to recognize the benefits of adherence.
Key Market Trends
Personalized Medicine
Approaches
Personalized medicine has become
a significant trend in the Oral Anti-Diabetic Drugs market. Recognizing that
diabetes is a highly heterogeneous condition, healthcare providers are
increasingly tailoring treatment plans to individual patient needs. Genetic
testing and biomarker research have enabled more precise drug selection and
dosing, optimized treatment outcomes and minimizing side effects. The concept
of "one size fits all" in diabetes management is gradually giving way
to tailored therapies that consider genetic factors, comorbidities, and patient
preferences. This trend is enhancing the effectiveness and safety of oral
anti-diabetic drugs.
Regulatory Support and
Expedited Approvals
Regulatory bodies worldwide have
shown a commitment to addressing the diabetes epidemic by streamlining the
approval process for oral anti-diabetic drugs. The urgency of the diabetes
challenge has prompted regulatory agencies to provide accelerated pathways for
drug approval, allowing innovative medications to reach the market more
quickly. This regulatory support has encouraged pharmaceutical companies to
invest in diabetes research and development, resulting in a pipeline of
promising oral anti-diabetic drugs. The faster introduction of new medications
to the market benefits patients and healthcare systems alike.
Innovations in Drug
Formulations
One of the most prominent trends
in the Oral Anti-Diabetic Drugs market is the continuous advancement of drug
formulations. Pharmaceutical companies are investing in research and
development to create more effective, safer, and patient-friendly medications.
Innovations such as oral Glucagon-Like Peptide-1 (GLP-1) receptor agonists,
fixed-dose combination therapies, and extended-release formulations have
expanded treatment options and improved patient adherence. Oral GLP-1 receptor
agonists, for instance, have emerged as a groundbreaking development, offering
the benefits of GLP-1 therapy in a more convenient tablet form. This has
increased accessibility and acceptance among patients who may have previously
been reluctant to use injectable GLP-1 agonists.
Segmental Insights
Drugs Insights
Based on the drugs, the Biguanides
segment emerged as the dominant player in the global market for Oral
Anti-Diabetic Drugs Market in 2024. This is on account of the efficacy and
widespread use of Biguanides in diabetes management. Biguanides, with metformin
being the most well-known representative, have long been a cornerstone in the
treatment of type 2 diabetes. Metformin, the most prescribed Biguanide, has a
proven track record of effectively lowering blood glucose levels. It primarily
works by reducing the liver's glucose production and enhancing insulin
sensitivity in peripheral tissues. Its efficacy and safety profile have made it
a first-line treatment for type 2 diabetes. Generic versions of metformin are
widely available, making it a cost-effective option for both patients and
healthcare systems. Moreover, Metformin
is often used in combination with other oral anti-diabetic drugs, enhancing its
versatility in treatment plans. Fixed-dose combination therapies that include
metformin are readily available, simplifying medication regimens and improving
patient adherence.
The dominance of the Biguanides
segment, particularly metformin, in the global Oral Anti-Diabetic Drugs market
in 2022 is a reflection of its well-established efficacy, safety profile,
cardiovascular benefits, weight-neutral or weight-loss effects, and cost-effectiveness.
As diabetes continues to be a prevalent global health concern, Biguanides are
expected to maintain their prominent position in diabetes management
strategies, offering hope and improved outcomes for individuals living with
this chronic condition.
Download Free Sample Report
Regional Insights
North America emerged as the
dominant player in the global Oral Anti-Diabetic Drugs Market in 2022, holding
the largest market share. This is on account of advanced healthcare infrastructure,
high prevalence of diabetes, and a robust pharmaceutical industry. North
America is home to some of the world's largest pharmaceutical companies with a
strong focus on diabetes research and development. These companies invest
heavily in developing innovative oral anti-diabetic drugs, which are readily
available to patients in the region. Regulatory agencies in North America, such
as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain
rigorous standards for drug approval. The stringent regulatory environment
ensures that only safe and effective medications enter the market, instilling
confidence in healthcare providers and patients.
Asia-Pacific is anticipated to
hold the largest share in the coming years, on account of its rapidly expanding population, increasing
prevalence of diabetes, and growing awareness of diabetes management. As
lifestyles change and urbanization continues, the Asia-Pacific region is
expected to experience a growing demand for oral anti-diabetic drugs, making it
a pivotal player in the global market landscape.
Recent Developments
- In April 2024, Sanofi India Limited has launched its’ new diabetes drug Soliqua® after having received the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua® is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
- In March 2025, American pharmaceutical major Eli Lilly and Company launched its diabetes and obesity management drug Mounjaro (tirzepatide) in India. The company launched the drug in a single-dose vial following marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).
- In December 2024, the Food and Drug Administration (FDA) approved generic liraglutide, recalled Monoject™ insulin syringes, and updated the safety labels for fezolinetant and drugs containing canagliflozin and dapagliflozin.
- In June 2024, AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on positive results from the paediatric T2NOW Phase III trial.2 Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control.
Key Market Players
- KONINKLIJKE
PHILIPS N.V.
- Sanofi
S.A.
- Eli
Lilly and Company
- AstraZeneca
- Astellas
Pharma Inc.
- Johnson
& Johnson (Janssen Pharmaceuticals)
- Boehringer
Ingelheim
- Merck
And Co.
- Bristol
Myers Squibb Company
- Novartis
AG
|
By Drugs
|
By End Users
|
By Region
|
- Biguanides
- Alpha-glucosidase
inhibitors
- Dopamine
-D2 Receptor Agonist
- Sodium-glucose
Cotransport -2 (SGLT-2) inhibitor
- Dipeptidyl
Peptidase - 4 (DPP-4) Inhibitors
- Sulfonylureas
- Meglitinides
|
- Hospitals
- Homecare
- Speciality Centers
- Others
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Oral
Anti-Diabetic Drugs Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Oral
Anti-Diabetic Drugs Market, By Drugs:
o Biguanides
o Alpha-glucosidase
inhibitors
o Dopamine
-D2 Receptor Agonist
o Sodium-glucose
Cotransport -2 (SGLT-2) inhibitor
o Dipeptidyl
Peptidase - 4 (DPP-4) Inhibitors
o Sulfonylureas
o Meglitinides
- Oral
Anti-Diabetic Drugs Market, By End Users:
o Hospitals
o Homecare
o Speciality
Centers
o Others
- Oral
Anti-Diabetic Drugs Market, By Region:
o North
America
§ United
States
§ Canada
§ Mexico
o Europe
§ France
§ United
Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South
Korea
o South
America
§ Brazil
§ Argentina
§ Colombia
o Middle
East & Africa
§ South
Africa
§ Saudi
Arabia
§ UAE
§ Kuwait
§ Turkey
§ Egypt
Competitive Landscape
Company Profiles: Detailed
analysis of the major companies present in the Global Oral Anti-Diabetic Drugs
Market.
Available Customizations:
Global Oral Anti-Diabetic Drugs
Market report with the given market data, Tech Sci Research offers
customizations according to a company's specific needs. The following
customization options are available for the report:
Company Information
- Detailed
analysis and profiling of additional market players (up to five).
Global Oral Anti-Diabetic
Drugs Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at sales@techsciresearch.com